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analysed retrospectively. The study was approved by the Local Ethics Committee. All FNACs were performed under ultrasound (US) guidance. Results were classified as unsatisfactory (non-diagnostic), benign, or malignant/suspicious (undetermined). Unsatisfactory aspirates were excluded from further analysis. The results were classified as unsatisfactory if there were fewer than ten groups of cells, each containing at least ten elements. Nodular goitre with or without regressive changes, granulomatous (de Quervain's) thyroiditis, and chronic lymphocytic inflammation of variable intensity interpreted as either focal lymphocytic thyroiditis or HT were included as benign. The 'malignant/ /suspicious' category included follicular neoplasia, papillary carcinoma, anaplastic carcinoma, medullary carcinoma, lymphoma, and metastatic tumours. These cases were diagnosed either as unequivocally malignant or with varying degrees of certainty. Cases with uncertain cytological findings that could not rule out malignancy were also included in the malignant category. The histopathological examination was performed after surgery (hemithyroidectomy or total thyroidectomy). The histological results were classified as benign (nodular goitre, follicular adenoma, or HT) or malignant (follicular carcinoma, papillary carcinoma, anaplastic carcinoma, medullary carcinoma, lymphoma, or metastatic neoplasms). Anaplastic, medullary and metastatic tumours together with lymphoma were excluded from final analysis. Since it is virtually impossible to identify papillary microcarcinomas by aspiration cytology (these neoplasms were found only by chance in patients operated for suspicious FNAC from another nodule), and since these tumours have a negligible malignant potential, incidentally histologically identified microcarcinomas were also included as benign lesions.
Altogether 823 patients underwent FNAC several times. A patient was considered positive when at least one of the cytological results was classified as suspicious/malignant. The result was repeatedly non-diagnostic in 305 cases. After exclusion of 17 lymphomas,
Introduction
Among endocrine tumours, thyroid cancer (TC) is the most common malignancy. According to the National Oncological Registry of the Czech Republic, the 2011 incidence of malignant thyroid neoplasms was 6.6/100,000 individuals [1] . Papillary thyroid cancer (PTC) is the most frequent TC, representing 70-80% of all TCs. Hashimoto's thyroiditis (HT) is the most common autoimmune thyroid disease, with an incidence of 30-150 per 100,000 individuals worldwide and striking predominance in females (5-20:1) . The relationship between HT and TC has not yet been fully ascertained. According to recent review [2] , a significant difference was observed between population-based studies of fine-needle aspiration cytology (FNAC) and thyroidectomy studies. In population-based studies of FNAC from thyroid nodules, no positive correlation was detected between HT and PTC, and the prevalence of PTC in patients with HT was 1.2% with an average risk ratio of 0.69. By contrast, in studies evaluating histology after thyroidectomy, a positive relationship was reported: the prevalence of PTC in patients with HT was 27.56% with an average risk ratio of 1.59 [2] . Unfortunately, the studies evaluated in that review were vulnerable to bias. In a group of patients with HT, the risk of developing TC was 1.68-fold higher than in a control cohort of non-HT patients [3] . In another study, the incidence of PTC was higher only in patients with a nodular form of HT compared to patients with nodular goitre without HT [4] . HT was present in 23.2% of patients with PTC in a recent meta-analysis and was associated with favourable clinicopathological features [5] . Thyroid-stimulating hormone (TSH) levels, starting with the normal range, were positively associated with PTC in patients with HT, who underwent thyroidectomy [6, 7] ; however, in another study, the TSH concentration was not different between patients with PTC or benign disease [8] . Thus, the relationship between anti-thyroid antibodies and the incidence of thyroid carcinoma (TC) remains controversial. In several studies, positivity for thyroid peroxidase antibody did not correlate with the malignancy rate [1, 4] while in other studies it showed inverse correlation with malignancy rate [9] . By contrast, anti-thyroglobulin (ATG) antibody positivity was associated with a slightly increased relative risk of thyroid carcinoma [1, 3, 10, 11] .
The present retrospective study of human clinical specimens investigated FNAC and pathology results to evaluate their association with HT, serum TSH levels, and anti-thyroid antibody positivity.
Material and methods
The results of 6411 FNAC of thyroid nodules performed in 5333 adult patients (14.1% men and 85.9% women) between 1991 and 2014 in the Endocrinology Unit were Thyroiditis and PTC incidence Filip Gabalec et al.
Statistics
The odds ratio (OR) for the existence of TC in the presence of HT, ATG, and anti-thyroid peroxidase (ATP) antibody positivity and low TSH (< 0.4 mIU/L) were calculated. The 95% confidence intervals (CI) were determined using online biostatistical software (http:// statpages.org/ctab2x2.html). Fisher's exact test and Chi square test were used, and a two-tailed p value ≤ 0.05 was considered statistically significant.
Results

Cytological studies
FNAC results were evaluated in 4947 patients. 
TSH levels
The level of TSH measured at the time of FNAC was available in 2268 patients. The malignancy rate was calculated based on the TSH level, which was either low (< 0.4 mIU/L) or higher (≥ 0.4 mIU/L) (Table III) . Low TSH was associated with a low probability of dif- 
009).
For HTpos patients the OR for malignancy in case of low TSH was 0.8, both in the cytological and histological studies, and the difference did not reach statistical significance (p = 0.704 and p = 0.835, respectively). Interpretation is difficult since the number of such cases was low. For HTneg patients, the malignancy rate was lower in case of low TSH 10.9% vs. 22.6% (OR 0.417, 95% CI 0.237-0.727, p = 0.001) in histological series and 9.6 vs. 16.7 (OR 0.529, 95% CI 0.386-0.722, p < 0.001) in cytological series.
Antibody positivity
The association of the FNAC results and surgical specimen histology with the presence of ATP and ATG autoantibodies is summarised in Table IV. The malignancy rate showed no correlation with the autoimmune status.
Discussion
The relationship between HT and thyroid carcinoma was proposed for the first time by Dailey in 1955 [13] . His work was based on surgical pathology data; however, in 1985, Holm et al. [14] published results from a 22-year study of patients with HT, in which only 2 of 829 patients developed TC. Many subsequent studies were published with controversial results. Among surgical studies, some demonstrated an association between HT [15] [16] [17] [18] [19] [20] and TC, whereas others did not [21, 22] . In a systematic review published by Jankovic et al. [2] , surgical studies showed a high incidence of PTC in HT. The average rate in eight retrospective thyroidectomy studies was 27.56%.
Recently, in a large series of 8524 patients who underwent surgery, Zhang also observed a significantly higher incidence of PTC in HTpos (29.4%) than in HTneg (19.4%) patients [23] . We also found a significantly higher incidence of TC in HTpos patients in our histological data. The prevalence was 29.5% for all differentiated TC. By contrast, several surgical studies reported that thyroid nodules are not more likely to be malignant in patients with HT than in patients without HT [22, 24] . Unfortunately, since the decision for surgery is mostly based on suspicious cytology results, any demonstration of association between HT and PTC in surgical studies is strongly affected by a serious selection bias [2, 25] . The retrospective character of studies is another disadvantage. Differences in results between Table III . OR in this Table evaluates Malignancy rate (%) 9. individual studies may be caused, at least in part, by differences in the histopathological evaluation of the extent of lymphocytic infiltration in the tissue [24] . Controversial results were also reported in population-based studies of thyroid nodules by FNAC. Some studies reported an association between HT and TC [4, 6, 8] , whereas others did not [25] [26] [27] [28] [29] [30] [31] . Possible sources of bias in Boi's [6] and Fiore's [4, 28] studies were discussed previously [25] . In a systematic review of cytological studies, [2] no positive correlation was observed between HT and PTC, and the prevalence of PTC in patients with HT was 1.2% with an average risk ratio of 0.69 [2] . Similar results were published recently in a large cytological series of 2504 consecutive patients, in which the prevalence of results suggestive or indicative of malignancy was not different between the groups studied [25] . Similarly to Castagna et al., [25] we analysed cytology and surgical specimen histology results in the same group of patients. Sample size is one of the strengths of our study. Our analysis of FNAC in 5314 patients showed no difference in risk of TC between patients with HT and patients without HT. Incidental microcarcinomas (less than 10 mm) were considered benign in histological series. There were 7 microcarcinomas with clinical diagnosis of Hashimoto thyroiditis and 33 in other diagnoses. We recalculated statistics considering them as malignant histology and the result did not change considerably.
High levels of TSH are associated with increased risk of TC [8, 10, 25, 28, 32, 33] . This was well-demonstrated in a review by McLeod et al.; [34] however, studies evaluating thyroid autoimmunity reported a lower OR for TC than other studies. In our study, we divided the population according to TSH level using a threshold of 0.4 mIU/L. In contrast to previous studies, we did not find any statistically significant difference in the incidence of malignant/suspicious FNAC result or histologically proven carcinoma between HT patients with normal TSH and HT patients with low TSH. This finding was published previously, [1] but in our series the number of histologically verified patients with HT was small. Among patients with nodular goitre, but not among patients with HT, the malignancy rate of TC was lower in patients with low TSH than in patients with normal TSH.
The relationship between thyroid autoantibodies and malignancy is controversial. Boelaert et al. [10] did not find any relationship between ATP antibody positivity and cancer risk after correction for TSH level. These results were also confirmed by others [4] . By contrast, in the study by Boi et al., positivity for autoantibodies (the authors did not specify whether thyroglobulin or thyroid peroxidase was assessed) was associated with increased probability of Bethesda IV category FNAC in patients under 53 years of age (OR, 2.29). Wong et al. [35] found that in patients with a previous benign FNAC result, malignant neoplasms confirmed by histology were more frequent in the presence than in the absence of thyroid antibodies (OR, 2.16). Similarly, in the study by Paparodis et al., [9] in patients with HT who were either euthyroid or treated with a high thyroxine dose, high ATP levels were significantly associated with a decreased incidence of TC.
As to ATG autoantibody levels, Kim et al. [8] first reported an association between ATG positivity and TC (OR, 1.61), and this finding was confirmed by subsequent studies; however, a lack of association was reported too. [35] In our series, we were not able to demonstrate any association between ATG or ATP antibody levels and cancer risk.
In conclusion, we confirmed, in a large patient population, no association between HT and TC based on cytology results. We also confirmed the fact that studies based on surgical specimens are strongly affected by selection bias. Low TSH levels are associated with a decreased risk of TC in patients with nodular goitre without HT; however, this could not be proven in patients with HT in this series. In addition, the ATG and ATP autoantibody status had no impact on cancer risk.
